Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / PCA3

PCA3

Basics

Aliases:
This biomarker is also known as:
  • prostate cancer associated transcript 3 (non-protein coding),
  • prostate cancer antigen 3,
  • PCAT3,
  • non-protein coding RNA 19,
  • NCRNA00019,
  • DD3,
  • prostate cancer antigen 3 (non-protein coding),

View in BioMuta

Description…

The prostate cancer antigen 3 (PCA3) gene is a highly specific biomarker upregulated in prostate cancer. Because there is no extensive open reading frame, the gene is thought to express a noncoding RNA. The FDA has approved an assay for prostate cancer that uses the ratio of PCA3 RNA to PSA RNA in urine. The assay is used to help physicians determine the need for repeat prostate biopsies in men 50 years of age or older who have had a previous negative biopsy. When used in conjunction with other clinical information, the use of this test can reduce the need for unnecessary prostate biopsies.

Attributes

QA State: Curated
Type: Gene
Short Name:
HGNC Name: PCA3

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Prostate

Attributes

Phase: Three
QA State: Curated

Overview

The prostate cancer antigen 3 (PCA3) gene is a highly specific biomarker upregulated in prostate cancer. The PCA3 gene (prostate cancer antigen 3) is a non-coding gene that is over-expressed in prostate cancer. PCA3 in conjunction with other clinical tools has been shown to be as effective as the PSA (prostate specific antigen) assay in predicting the presence of prostate cancer. The FDA recently approved the first molecular test that uses PCA3 to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.

Performance Comment

The FDA has approved an assay for prostate cancer that uses the ratio of PCA3 RNA to PSA RNA in urine. The assay is used to help physicians determine the need for repeat prostate biopsies in men 50 years of age or older who have had a previous negative biopsy. When used in conjunction with other clinical information, the use of this test can reduce the need for unnecessary prostate biopsies.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 02/12/2015

Please register for the 29th EDRN Steering Committee Meeting in Atlanta, GA from March 31-April 2, 2015. The registration page has information about booking hotel rooms and a draft agenda of the meeting.

Announcement